BMS reports 2% revenue loss in 2023 after Revlimid generics hurt sales
Bristol Myers Squibb has reported a 2% revenue decrease from 2022 as it focuses on business development to counteract patent losses.
Bristol Myers Squibb has reported a 2% revenue decrease from 2022 as it focuses on business development to counteract patent losses.
What's Your Reaction?
